Expansion into preventive and advanced medical care through making プリメディカ a wholly owned subsidiary
First written in FY2024. 1 of 3 entries say "Cited as achieved", first in FY2025-H1. Latest entry: FY2025.
0 other companies' latest entry also says "Advanced".
- FY2025AdvancedAnnual report
「In addition, our consolidated subsidiary, 株式会社プリメディカ, provides disease-risk testing services under the basic policy of “contributing to extending healthy life expectancy by identifying the risk of diseases that may develop in the future and encouraging behavioral change.”」
Following the full acquisition of プリメディカ, disease-risk testing services and research and development activities, including LOX-index and Flora Scan, were incorporated into the consolidated business in the preventive and advanced medicine fields. - FY2025-H1Cited as achievedAnnual report
「Following the acquisition of shares in 株式会社プリメディカ, the Company has included the company and its subsidiary, 株式会社フローラディスカバリー, in the scope of consolidation.」
Following the acquisition of プリメディカ, the company and its subsidiary フローラディスカバリー were confirmed to have been included in the scope of consolidation. - FY2024First statedAnnual report
「At a meeting of its Board of Directors held on 30 April 2024, the Company resolved to acquire all shares of 株式会社プリメディカ and make it a subsidiary, and entered into a share transfer agreement on the same date.」
The Company acquired all shares of プリメディカ on 31 May 2024 and made it a wholly owned subsidiary. プリメディカ operates businesses in preventive medicine and research and development in cutting-edge medical technologies. The acquisition was based on its alignment with the expansion of the Company’s business into the prevention and preemptive healthcare fields under its 2027 Medium-Term Vision.